Halozyme Therapeutics’ Phase III HALO-301 trial investigating PEGPH20 for first-line pancreatic cancer with high levels of tumour hyaluronan (HA-high) has so far enrolled...
Read More...
The post Halozyme enrols 150 of 570 patients for Phase III pancreatic cancer trial appeared first on Pharmaceutical Technology.